A Study of EGb 761® (Tanakan®) in Dementia of Alzheimer Type Onset in Patients Suffering From Memory Complaints

Ipsen2,878 enrolled

Overview

The purpose of this study is to determine whether Tanakan® is effective at slowing the progression from memory complaint to dementia of Alzheimer's type.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

2,878

Conditions

Memory Disorders, Age-Related Retention Disorders, Cognitive

Interventions

EGb 761® (Tanakan®)DRUG

120 mg, 1 tablet twice a day, oral route, during 5 years.

PlaceboOTHER

1 tablet twice a day, oral route, during 5 years.

Eligibility

Sex: ALLMin age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Spontaneously reporting a memory complaint * Short anxiety battery test \< 6, (only if patient screened at GP site) * Geriatric depression scale \< 15 * Mini-mental state (MMS) \> 25 in GP's office (in hospital site MMS is done as complementary scale) Exclusion Criteria: * Objective memory impairment * Clinician rated dementia staging system \> 0.5 * Mini-mental state \< 25 * Dementia, past history of seizures, Parkinson disease

Locations (698)

Outcomes

Primary Outcomes

EGb 761® efficacy on conversion rate of memory complaint to dementia of Alzheimer type by a survival analysis